FIELD: chemistry.
SUBSTANCE: compounds with the formula are described and its pharmaceutically acceptable salts, where Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, m, n, p and q are as specified in the invention. The obtained compounds have the modulating activity regarding the 5-HT receptors. The pharmaceutical composition which contains the compounds with formula (I) and used in treatment of certain central nervous system diseases is also described.
EFFECT: novel compound group with useful biological properties is obtained.
10 cl, 2 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
BENZOXAZINE DERIVATIVES AND THEIR APPLICATION | 2004 |
|
RU2354651C2 |
COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | 2005 |
|
RU2420318C2 |
BICYCLIC HETEROCYCLES AND USE THEREOF AS HIV INTEGRASE INHIBITORS | 2005 |
|
RU2381228C2 |
MALONAMIDE DERIVATIVES AS γ-SECRETASE INHIBITORS | 2004 |
|
RU2330849C2 |
HETEROCYCLIC COMPOUNDS | 2019 |
|
RU2809257C2 |
BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USE THEREOF | 2005 |
|
RU2382036C2 |
NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
MAGL INHIBITORS | 2017 |
|
RU2754536C1 |
PHARMACEUTICAL COMPOSITION (VARIANTS), DERIVATIVES OF 3,5-DIPHENYL-1,2,4-TRIAZOLES COMPRISING THEREOF | 1997 |
|
RU2208010C2 |
BENZIMIDAZOLE AND INDOLE DERIVATIVES AS SELECTIVE 5-HT6 AND/OR 5-HT2A RECEPTOR ANTAGONISTS | 2006 |
|
RU2415138C2 |
Authors
Dates
2008-07-10—Published
2003-11-04—Filed